ISBN: 9786139844531 - pet/ct correlation with molecular subtypes in metastatic breast cancer (8 Ergebnisse)

Zustand: New.

Taschenbuch. Zustand: Neu. PET/CT Correlation with Molecular Subtypes in Metastatic Breast Cancer | Hosna Moustafa (u. a.) | Taschenbuch | 72 S. | Englisch | 2018 | LAP LAMBERT Academic Publishing | EAN 9786139844531 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu.…

Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -PET/CT has higher sensitivity, specificity and accuracy in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with MBC and monitoring the therapy response in relation to different molecular sub-types. Material and Methods: 40 patients classified into 4 molecular sub-types; Luminal A like 13 patients, Luminal B+ sub type 15 patients, Luminal B- sub type 4 patients and Basal like sub type 8 patients. All patients performed PET-CT before treatment, while 34 patients perform PET-CT at end of therapy. Results: on lesion based analysis 120 metastatic lesions are seen in CT and bone scan and 76 lesions are seen in PET/CT. During follow up, the majority of luminal A group showed complete response to therapy luminal B+ subgroup showed partial response and most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular sub-types. The mean SUV max showed relation to the different molecular sub-types. 72 pp. Englisch.…

Zustand: New. Print on Demand.

Zustand: New. PRINT ON DEMAND.

Taschenbuch. Zustand: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - PET/CT has higher sensitivity, specificity and accuracy in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with MBC and monitoring the therapy response in relation to different molecular sub-types. Material and Methods: 40 patients classified into 4 molecular sub-types; Luminal A like 13 patients, Luminal B+ sub type 15 patients, Luminal B- sub type 4 patients and Basal like sub type 8 patients. All patients performed PET-CT before treatment, while 34 patients perform PET-CT at end of therapy. Results: on lesion based analysis 120 metastatic lesions are seen in CT and bone scan and 76 lesions are seen in PET/CT. During follow up, the majority of luminal A group showed complete response to therapy luminal B+ subgroup showed partial response and most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular sub-types. The mean SUV max showed relation to the different molecular sub-types.…

Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Moustafa HosnaH. Moustafa: Doctorate degree, 11/1979, Professor of Nuclear Medicine, Cairo University (28/2/1990 - till now), Head of AFRA Nuclear Medicine project in Egypt (2003-2030), Head of Egyptian Society of Nuclear Medicine S.…

Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -PET/CT has higher sensitivity, specificity and accuracy in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with MBC and monitoring the therapy response in relation to different molecular sub-types. Material and Methods: 40 patients classified into 4 molecular sub-types; Luminal A like 13 patients, Luminal B+ sub type 15 patients, Luminal B- sub type 4 patients and Basal like sub type 8 patients. All patients performed PET-CT before treatment, while 34 patients perform PET-CT at end of therapy. Results: on lesion based analysis 120 metastatic lesions are seen in CT and bone scan and 76 lesions are seen in PET/CT. During follow up, the majority of luminal A group showed complete response to therapy luminal B+ subgroup showed partial response and most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular sub-types. The mean SUV max showed relation to the different molecular sub-types.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 72 pp. Englisch.…